ULCERATIVE COLITIS

This study tests if rupatadine, an allergy medicine, can help control inflammation and symptoms in people with mild-to-moderate ulcerative colitis. About 60 adults will take the drug and be monitored for safety and effectiveness. The goal is to manage the disease, not cure it.

This study follows about 200 adults in Japan with moderate to severe ulcerative colitis who are prescribed risankizumab by their doctors as part of routine care. Researchers will track changes in disease activity, like stool frequency and rectal bleeding, for up to 156 weeks. The…

This study looks at whether taking prebiotics (a type of fiber) can improve gut health and reduce symptoms in people with ulcerative colitis, a form of inflammatory bowel disease. About 70 adults with active symptoms will take a prebiotic supplement for 8 weeks. Researchers will …

This program offers continued access to vedolizumab, given as an IV infusion, for children and teenagers with moderate to severe ulcerative colitis or Crohn's disease who completed a prior study and still benefit from the treatment. It is designed for those without suitable alter…

This study tests a drug called risankizumab in children aged 2 to 18 with moderate to severe ulcerative colitis, a condition causing colon inflammation and bleeding. The trial will check how the drug works in the body, its safety, and its ability to reduce symptoms. Around 120 ch…

This study tests a steroid pill (budesonide) in children aged 5 to 17 with mild to moderate ulcerative colitis, a bowel disease causing bleeding and diarrhea. The goal is to see if the pill can safely bring the disease into remission within 56 days. Participants may continue thei…

This study looks at the long-term safety of the drug vedolizumab in children with ulcerative colitis or Crohn's disease. It is for kids who already completed a previous vedolizumab study. Researchers will track side effects and major bowel-related events over time.

This study compares two approved drugs, risankizumab and vedolizumab, to see which works better for adults with moderate to severe ulcerative colitis who haven't tried targeted therapies before. About 530 participants will receive one of the two medications, and researchers will …

This study is for people who have both an autoimmune disorder (like rheumatoid arthritis, lupus, or multiple sclerosis) and advanced cancer that has spread or cannot be removed. It tests a drug called nivolumab, which helps the immune system fight cancer, given alone or with othe…

This study tests a new medicine called duvakitug for people with moderate to severe ulcerative colitis. Participants who already responded to duvakitug in an earlier study will continue treatment for up to 5 years to see if it safely maintains remission. The goal is to control th…

This early study tests whether stimulating a nerve in the lower back (sacral nerve stimulation) can safely reduce symptoms of ulcerative colitis. It includes 15 adults whose colitis is moderate-to-severe and hasn't improved with standard drugs. The main goal is to see if the trea…

This study is testing whether transplanting healthy stool bacteria into people with ulcerative colitis can help control the disease. It involves 85 adults with active colitis who will receive either the transplant or a placebo. The goal is to see if this approach is worth testing…

This study tests a drug called mirikizumab in children aged 2 to 17 with moderate to severe ulcerative colitis, a chronic bowel disease. The goal is to see if the drug can help control the disease and improve symptoms over 52 weeks. About 60 children who have not responded to oth…

This study follows 200 adults with moderate to severe ulcerative colitis who are prescribed risankizumab by their doctors in Germany and Austria. Researchers will track how well the drug controls symptoms like bleeding and frequent bowel movements over 52 weeks. The goal is to se…

This study tests whether taking frozen capsules containing healthy donor stool (or filtered stool) can safely help people with mild-to-moderate ulcerative colitis reach remission. About 129 adults who have not responded to standard treatments will take the capsules or a placebo f…

This study tests an oral medication called etrasimod in adolescents aged 12 to 17 with moderate-to-severe ulcerative colitis, a chronic gut condition. The goal is to see if the drug can safely reduce inflammation and bring the disease under control over 52 weeks. Participants who…

This study tests if breathing pure oxygen in a pressurized chamber (hyperbaric oxygen therapy) can help people hospitalized with moderate to severe ulcerative colitis feel better faster. About 126 adults will receive either real or fake (sham) treatment to see if it reduces bleed…

This study tests whether adding an experimental drug (LY4268989) to a standard treatment (mirikizumab) works better than the standard treatment alone for adults with moderate-to-severe ulcerative colitis. About 252 participants will receive either the combo or mirikizumab alone f…

This study tests whether a combination of two drugs, vedolizumab and tofacitinib, can help adults with moderate to severe ulcerative colitis achieve remission. Participants receive both drugs for 8 weeks, then those who respond continue with vedolizumab alone for 44 weeks. The go…

This study tests whether adding tirzepatide (a weight-loss drug) to mirikizumab (an anti-inflammatory drug) helps people with moderate-to-severe ulcerative colitis who are also overweight or obese. About 350 adults will receive either both drugs or mirikizumab alone for up to 52 …

This study tests a new oral drug called BRS201 in 20 adults with severe ulcerative colitis who have not improved with standard treatments. Participants take the drug twice daily for 4 weeks and attend 8 clinic visits for blood, stool, and urine tests. The goal is to see if BRS201…

This study tests whether adding a freeze-dried fecal transplant (LFMT) to standard biologic drugs (vedolizumab or ustekinumab) is safe and helps more people with ulcerative colitis reach remission. About 40 adults with active UC will receive either LFMT or a placebo alongside the…

This study looks at how well the drug upadacitinib (RINVOQ) controls symptoms of ulcerative colitis, a condition that causes inflammation and bleeding in the colon. About 400 adults in Germany, Austria, and Switzerland who are already prescribed the drug will be followed for up t…

This study tests two drugs, eltrekibart and mirikizumab, alone or together, in 140 adults with moderate-to-severe ulcerative colitis. The goal is to see if they can safely help patients achieve remission. Participants must have tried other treatments without success.

This study explores whether fecal transplants (capsules containing healthy donor stool) can improve quality of life and control inflammation in people newly diagnosed with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, or ulcerative colitis. T…

This study looks at whether vedolizumab can help people with moderate to severe ulcerative colitis or Crohn's disease achieve remission (no symptoms) after 14 weeks of treatment. About 400 adults aged 18 to 80 will receive vedolizumab first as an IV infusion, then as a shot under…

This study tests an experimental drug called MK-8690 for people with moderate to severe ulcerative colitis, a condition causing gut inflammation. About 100 adults will receive either the drug or a placebo to see if it helps achieve remission (fewer symptoms and healed gut lining)…

This study looks at the long-term safety of a drug called vedolizumab in children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who responded well to the drug in an earlier study will continue treatment, while others who did not respond well will…

This study tests a new medicine, duvakitug, to see if it can help people with moderate to severe ulcerative colitis feel better and reach remission. About 980 adults will receive either the drug or a placebo for up to 12 weeks. The goal is to reduce bowel urgency, bleeding, and i…

This study looks at the long-term safety of an oral medication called zasocitinib (TAK-279) for people with moderate to severe Crohn's disease or ulcerative colitis. Participants who responded to treatment in earlier studies can continue taking the drug for up to 2 years. The mai…

This study looks at whether removing certain food additives (like carrageenan and polysorbates) from the diet can help people with moderate ulcerative colitis. Seventy participants will be randomly assigned to either a normal healthy diet or one that avoids these additives for on…

This study looks at how well and how safely the drug mirikizumab works over a long period (about 3 years) in children and teenagers with moderate-to-severe ulcerative colitis or Crohn's disease. Participants must have already been in a previous mirikizumab study and may continue …

This study follows 120 people with ulcerative colitis in Sweden who are already prescribed tofacitinib as part of their routine care. Researchers will use registry data to see how many achieve remission and how well they stick with the treatment. The goal is to understand how the…

This study looks at whether a weight loss procedure called Endoscopic Sleeve Gastroplasty (ESG) is safe and effective for people with ulcerative colitis (UC) who are obese and need or have had colon removal surgery. About 12 participants will be enrolled. The goal is to help them…

This early-stage study is testing a probiotic pill called R-3750 in 36 adults with mild to moderate ulcerative colitis. The main goal is to see if the pill is safe and tolerable. Participants will take the probiotic by mouth and report their symptoms, while researchers check bloo…

This study tests a daily pill called filgotinib in about 80 children aged 8 to 17 with moderate to severe ulcerative colitis. The goal is to see if the drug can safely reduce symptoms and bring the disease under control. Participants take the medicine at home and visit the clinic…

This study tests a subcutaneous (under-the-skin) version of vedolizumab in children aged 2-17 with moderate to severe ulcerative colitis or Crohn's disease. About 70 kids who already responded to IV vedolizumab will receive the shot for up to 34 weeks. The goal is to see how the …

This program provides early access to upadacitinib for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis. It is for those who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the pot…

This study tests a new drug, RO7837195, for people with moderate-to-severe ulcerative colitis who haven't gotten better with other treatments. About 224 participants will receive either the drug or a placebo to see if it can bring the disease under control. The main goal is to ac…

This study tests a new drug called ISM5411 in 80 adults with active ulcerative colitis, a chronic bowel disease causing inflammation and discomfort. Participants will receive either the drug or a placebo to see if it safely reduces symptoms. The goal is to control the disease, no…

This study tests a remote monitoring app (MedicWise) for people with active Crohn's disease or ulcerative colitis. About 290 adults will use the app to track symptoms and health data, with the goal of spending more time in remission over 12 months. The app automatically collects …

This study tests an experimental drug called tilpisertib fosmecarbil (GS-5290) in 176 adults with moderate to severe ulcerative colitis. Participants will receive either the drug or a placebo for 12 weeks to see if it helps reduce symptoms like diarrhea, bleeding, and inflammatio…

This study tests whether giving several fecal microbiota transplants (FMT) works better than a single one to clear recurrent C. difficile infection in people with ulcerative colitis. About 64 adults with active colitis and repeat C. diff will receive either one or multiple infusi…

This study tests whether a diet made of familiar American foods like grilled meats, baked potatoes, and oatmeal can reduce inflammation and help control ulcerative colitis. About 122 adults aged 16-75 with mild to moderate symptoms will follow this diet for a set time. Researcher…

This study tests whether long-acting antibodies, given alone or together, can safely reduce inflammation and improve symptoms in adults with moderate-to-severe ulcerative colitis. About 645 participants will receive the treatment through an IV infusion followed by regular shots. …

This study tests a daily pill called filgotinib (200 mg) in about 94 Korean adults with moderate-to-severe ulcerative colitis. The main goal is to see if it can bring the disease into remission (quiet down symptoms) by week 10 or 22. Participants take the pill once a day and are …

This study tests whether adding the deworming drug mebendazole to standard mesalamine treatment can safely improve symptoms in people with mild-to-moderate ulcerative colitis. Researchers will measure changes in disease activity, blood markers, and symptom scores over time. The t…

This study tests an experimental drug called SAR442970 in 99 adults with moderate to severe ulcerative colitis. Participants receive either the drug or a placebo for 16 weeks, followed by a long-term extension where everyone can get the drug. The goal is to see if the drug can re…

This study follows about 80 Chinese adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib by their doctor. Researchers will track how well the drug controls symptoms like bloody diarrhea over one year, using only routine checkup data. The goal …

This study looks at whether eating more fermented foods like yogurt, kimchi, and sauerkraut can reduce gut inflammation and improve daily life for people with mild to moderate ulcerative colitis. About 21 adults with the condition will add these foods to their diet for a period o…

This study tests whether adding the antihistamine desloratadine to standard treatment (mesalamine) can reduce inflammation and disease activity in people with mild to moderate ulcerative colitis. About 44 adults aged 18 to 65 who are already on mesalamine will take either deslora…

This study tests whether a five-day diet that tricks the body into a fasting state can reduce inflammation and improve quality of life in people with mild to moderate ulcerative colitis. Participants will follow the diet for three cycles while researchers track symptoms like stoo…

This study looks at whether sleep changes can warn of a flare-up in people with Crohn's disease or ulcerative colitis. Researchers will track sleep patterns and disease activity in 216 patients in remission for one year. The goal is to find early signs of relapse, which could hel…

This study follows 450 adults who have early signs of inflammatory bowel disease (IBD) but no symptoms yet. Researchers want to learn how the disease progresses, what symptoms appear first, and how genetics and the immune system play a role. Participants are monitored over time w…

This study is testing a new educational tool designed for people with melanoma who also have an autoimmune disease (like rheumatoid arthritis or Crohn's disease) and may receive immune checkpoint inhibitor drugs. Researchers want to see if the tool is easy to use and helpful for …

This study looks at how pregnancy, childbirth, and breastfeeding affect inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers will track 945 women from the EPIMAD registry to count disease flares during and after pregnancy. The goal is to…

This study looks at how nutrition and body composition (like muscle mass) influence treatment results in people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Researchers will follow 300 patients starting new medical therapies or undergoi…

This study looks at how doctors around the world use a 'treat-to-target' approach for people with Crohn's disease or ulcerative colitis. Researchers will review medical records from 2,000 adults over 24 months to see if adjusting treatment based on regular check-ups leads to bett…

This study looks at how the immune system controls inflammation in the gut for people with Crohn's disease or ulcerative colitis. Up to 1,000 participants, from newborns to age 75, will receive standard medical care while researchers collect blood, tissue, and other samples. The …

This study looks at whether ultrasound can detect scarring (fibrosis) in the gut of people with ulcerative colitis. Researchers will compare ultrasound images with tissue samples from colonoscopies to develop new, non-invasive ways to measure disease. The goal is to improve diagn…

This study collects tissue and blood samples from 300 people with autoimmune diseases like Crohn's, multiple sclerosis, and celiac disease. Researchers will look for T cells that are active in inflamed tissues to find their targets. The goal is to discover new targets for future …

This study tests whether nicotinamide riboside, a vitamin-like supplement, is safe and practical for children with mild to moderate ulcerative colitis. About 40 participants will take the supplement and be followed for up to 12 months. The main goal is to see if the study is feas…

This study looks at how having inflammatory bowel disease (Crohn's or colitis) as a child affects job and education in adulthood. Researchers will survey 460 adults diagnosed before age 17 to compare their work and school achievements with the general population. The goal is to u…

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…

This study looks at whether robotic surgery is a good option for people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. About 100 adults having minimally invasive surgery for IBD will take part. The goal is to see if robotic surgery is tec…

This study is tracking 600 adults in South Korea who are already receiving vedolizumab injections for ulcerative colitis or Crohn's disease. Researchers will review medical records to see what side effects occur and how well the treatment works. No new treatments are given—this i…